Data Year:

For its 2025 fiscal year, MADRIGAL PHARMACEUTICALS, INC., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Rebecca Taub M.D.
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
Total Compensation $6,868,016 View details Pay Rank By Title In Biotechnology industry #14 View more
Carole Huntsman
Executive Vice President and Chief Commercial Officer
Total Compensation $5,441,736 View details Pay Rank By Title In Biotechnology industry #44 View more
Bill Sibold
President and Chief Executive Officer
Total Compensation $19,206,341 View details Pay Rank By Title In Biotechnology industry #34 View more
Mardi Dier
Executive Vice President and Chief Financial Officer
Total Compensation $6,085,089 View details Pay Rank By Title In Biotechnology industry #39 View more
Shannon Kelley
Executive Vice President and Chief Legal Counsel
Total Compensation $5,179,352 View details Pay Rank By Title In Biotechnology industry #46 View more
David Soergel M.D.
Executive Vice President and Chief Medical Officer
Total Compensation $9,190,678 View details Pay Rank By Title In Biotechnology industry #14 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at MADRIGAL PHARMACEUTICALS, INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. MADRIGAL PHARMACEUTICALS, INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. MADRIGAL PHARMACEUTICALS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Rebecca Taub M.D.
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
Total Cash $1,222,044 Equity $5,645,972 Other $0 $6,868,016
Carole Huntsman
Executive Vice President and Chief Commercial Officer
Total Cash $1,069,289 Equity $4,362,608 Other $9,839 $5,441,736
Bill Sibold
President and Chief Executive Officer
Total Cash $2,357,345 Equity $16,834,996 Other $14,000 $19,206,341
Mardi Dier
Executive Vice President and Chief Financial Officer
Total Cash $1,120,207 Equity $4,875,536 Other $89,346 $6,085,089
Shannon Kelley
Executive Vice President and Chief Legal Counsel
Total Cash $1,059,105 Equity $4,106,247 Other $14,000 $5,179,352
David Soergel M.D.
Executive Vice President and Chief Medical Officer
Total Cash $1,077,282 Equity $8,113,396 Other $0 $9,190,678
For its 2025 fiscal year, MADRIGAL PHARMACEUTICALS, INC., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Bill Sibold CEO Pay $19,206,341 Median Employee Pay $403,403 CEO Pay Ratio 48:1
For its 2025 fiscal year, MADRIGAL PHARMACEUTICALS, INC., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Daniel J. Brennan Total Cash $613,097
Fred B. Craves, Ph.D. Total Cash $39,375
Jacqualyn A. Fouse, Ph.D. Total Cash $761,744
James M. Daly Total Cash $477,022
Julian C. Baker Total Cash $503,397
Kenneth M. Bate Total Cash $488,397
Paul A. Friedman, M.D. Total Cash $469,147
Raymond Cheong, Ph.D., M.D. Total Cash $494,897
Richard S. Levy, M.D. Total Cash $494,897
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.